In a regulatory filing, BioMarin stated: “We recently received a subpoena from the U.S. Department of Justice requesting that we produce certain documents regarding our sponsored testing programs relating to VIMIZIM and NAGLAZYME. We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or our other operations or programs, will not be found to violate such laws.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin price target lowered to $107 from $115 at Piper Sandler
- BioMarin price target lowered to $130 from $150 at BofA
- BioMarin sees 2024 non-GAAP EPS $2.60-$2.80, consensus $1.96
- BioMarin reports Q4 non-GAAP EPS 49c, consensus 23c
- BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
